This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental material
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gavin, P. J.
Right arrow Articles by Peterson, L. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gavin, P. J.
Right arrow Articles by Peterson, L. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2006, p. 2244-2247, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.00381-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-ß-Lactamase-Producing Escherichia coli and Klebsiella Species{dagger}

Patrick J. Gavin,1* Mira T. Suseno,1 Richard B. Thomson Jr.,1 J. Michael Gaydos,2 Carl L. Pierson,3 Diane C. Halstead,4 Jaber Aslanzadeh,5 Stephen Brecher,6 Coleman Rotstein,7 Stephen E. Brossette,8 and Lance R. Peterson1

Evanston Northwestern Healthcare, Evanston, Illinois,1 Cleveland Veterans Affairs Medical Center, Cleveland, Ohio,2 Hartford Hospital, Hartford, Connecticut,3 University of Michigan Health System, Ann Arbor, Michigan,4 North Florida Pathology Associates and Baptist Health, Jacksonville, Florida,5 Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts,6 McMaster University, Hamilton Health Sciences, Hamilton, Ontario,7 MedMined, Birmingham, Alabama8

Received 23 March 2005/ Returned for modification 24 July 2005/ Accepted 17 March 2006

We assessed infections caused by extended-spectrum-ß-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 µg/ml. All six urinary infections responded to treatment regardless of susceptibility.

* Corresponding author. Mailing address: Department of Pathology and Laboratory Medicine, Microbiology Rm. 1736, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201. Phone: (847) 570 2744. Fax: (847) 733 5314. E-mail: pgavin{at}enh.org.

{dagger} Supplemental material for this article may found at http://aac.asm.org/.

Antimicrobial Agents and Chemotherapy, June 2006, p. 2244-2247, Vol. 50, No. 6
0066-4804/06/$08.00+0     doi:10.1128/AAC.00381-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • MacGowan, A. P., on behalf of the BSAC Working Parties on Resistanc, (2008). Clinical implications of antimicrobial resistance for therapy. J Antimicrob Chemother 62: ii105-ii114 [Abstract] [Full Text]  
  • Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E. M., Posteraro, B., Fiori, B., Citton, R., D'Inzeo, T., Fadda, G., Cauda, R., Spanu, T. (2007). Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-{beta}-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment. Antimicrob. Agents Chemother. 51: 1987-1994 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»